Clinical trials: Pulmonary Artery Hypertension
LEVOSIMENDAN, PULMONARY THROMBOENDARTERECTOMY
The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy
A single-center pilot prospective randomized placebo-controlled double-blind clinical trial. Study objective - to investigate the efficacy and safety of levosimendan in patients in the perioperative period following pulmonary…
- Conditions
- LEVOSIMENDAN, PULMONARY THROMBOENDARTERECTOMY, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Hypertension
- Trial name
- LEVO-CTEPH (NCT07914933)
- Testing
- Infusion of levosimendan
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Pulmonary Arterial Hypertension
Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension
The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- PADN-CFDA (NCT03282266)
- Testing
- PADN
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
This prospective, non-interventional, multi-center study documents observational data on subjects under routine treatment of Pulmonary Arterial Hypertension, functional class III with inhaled Iloprost administered with I-Neb AAD…
- Trial name
- DAILY (NCT01781052)
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
This study will determine the safety and feasibility of using a β-blocker (in this case carvedilol) in the treatment of pediatric patients with Left Heart Failure (LHF) in children with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01723371
- Testing
- Carvedilol
- Where
- Canada
- Sponsor
- The Hospital for Sick Children
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic illness characterized by increased pulmonary pressures resulting in right heart failure and premature death.
- Trial name
- NCT02080533
- Testing
- Slow-paced respiration therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Primary Pulmonary Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT03992755
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 25 sites in United States
- Volunteers
- 92 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
A Mobile Health Intervention in Pulmonary Arterial Hypertension
This study proposes the use of a mobile health intervention (utilizing a smart phone app) to encourage increased exercise in PAH patients.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
- Trial name
- mHealth (NCT03069716)
- Testing
- Smartphone Text Messaging, Fitbit Charge HR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Hypertension, Pulmonary
The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH
Pulmonary hypertension (PH) is a progressive disease with high mortality rate, but due to the development of drugs, the prognosis of the disease has improved.
- Trial name
- NCT02647060
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related…
- Trial name
- EVOLVE (NCT05060315)
- Testing
- Remunity Pump for Remodulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- United Therapeutics
Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension, Chronic Cardiorespiratory Disease
Effect of Short-term Oxygen During CPET in Pulmonary Hypertension
In a randomized, sham-controlled trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with…
- Trial name
- ExOx-CPET (NCT01748474)
- Testing
- Supplemental oxygen via a mask
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Hypertension, Pulmonary
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary…
- Trial name
- ATMOS (NCT03754660)
- Testing
- BAY1237592
- Where
- 8 sites in Austria, Czechia and 2 more
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure.
- Trial name
- RETRIEVE (NCT01905189)
- Testing
- Resynchronization therapy of right ventricle
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Caen
Asthma, Cardiovascular Diseases
Trial to Enhance Adherence to Multiple Guidelines
To evaluate whether the innovative multimethod assessment process/participatory quality improvement (MAP/PQI) intervention increases adherence to multiple cardiorespiratory guidelines in primary care practice.
- Conditions
- Asthma, Cardiovascular Diseases, Atherosclerosis, Diabetes Mellitus
- Trial name
- ULTRA (NCT00201227)
- Testing
- practice guideline adherence
- Volunteers
- 60 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Hypertension, Pulmonary Arterial Hypertension
129 Xenon Imaging in Patients Treated With Sotatercept
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
- Trial name
- Sox-PH (NCT06351345)
- Testing
- 129Xe Hyperpolarized
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Arterial Hypertension
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06137742
- Testing
- PF-07868489
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Hypertension
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass
Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of…
- Trial name
- MUSCLE UP-PH (NCT07132788)
- Testing
- blood draw, Short Performance Physical Battery, Grip strength test
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension, PAH
Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
The study is designed as a non-interventional, multicenter, prospective single-arm study to observe the therapy with REMODULIN (Treprostinil) applicated by an implantable pump in patients with pulmonary arterial hypertension…
- Trial name
- LPS-II (NCT04309838)
- Testing
- Treprostinil via implanted pump
- Where
- 8 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Medicine Greifswald